Medicine
Erbitux 200 mg/100 mL injection
Erbitux 200 mg/100 mL injection is a prescription medicine containing Cetuximab for intravenous use, marketed by ImClone, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials under refrigeration at 2° C to 8° C (36° F to 46° F). Do not…
Key facts
- Active ingredient (INN)
- Cetuximab
- Brand
- Erbitux
- Strength
- 200 mg/100 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 100 mL
- Marketing authorisation holder
- ImClone
- Manufacturer
- ImClone
- Origin register
- US FDA, United States
- Storage
- Store vials under refrigeration at 2° C to 8° C (36° F to 46° F). Do not freeze or shake. Discard any remaining solution in the infusion container after 8 hours at controlled room temperature or after 12 hours at 2° C to 8° C. Increased particulate formation may occur at temperatures at or below 0° C (32° F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FE01 Cetuximab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 October 2007
- Identifiers
- RxCUI 1657658, 1657660, 1657663 +1DailyMed set ID 8bc6397e-4bd8-4d37-a007-a327e4da34d9NDC 66733-958Application BLA125084
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 66733-958-23 | ImClone | 2 October 2007 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cetuximab
Clinical summary
Cetuximab is an epidermal growth factor receptor antagonist indicated for treatment of head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy, among other approved uses. MedsAcross supplies Cetuximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CetuximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ERBITUX prescribing information (ImClone) · U.S. National Library of Medicine, DailyMed
- Erbitux: European public assessment report (EPAR) · European Medicines Agency
Need Erbitux 200 mg/100 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.